Brief: Arch Biopartners Receives Approval From Ethics Committee In Turkey To Proceed With Phase Ii Cardiac Surgery
21/12/2023 12:37
Dec 21 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES APPROVAL FROM ETHICS COMMITTEE
IN
TURKEY TO PROCEED WITH PHASE II CARDIAC SURGERY ASSOCIATED-ACUTE
KIDNEY INJURY TRIAL FOR LSALT PEPTIDE
Source text for Eikon: ID:nGNX5VwKTd
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide